• The SMA NBS Alliance’s objective is for 100% of babies born in Europe to be screened for SMA by 2025.
• SMA Europe estimates that 25% of newborn babies in the EU were screened for SMA at the end of 2021.
• By the end of 2022, SMA Europe estimates 45% of newborns born in Europe will be screened for SMA. 40% considering the European continent including Russia and Turkey.

The Romanian Association SMACARE in partnership with SMA Europe and the European Alliance for SMA NBS is organizing an event on 25 November in Bucharest, Romania at the Crowne Plaza Hotel Bucharest.

On September 15, 2022, the regional government of Galicia, Spain announced they would add three new diseases to the regional screening programme, including SMA, and begin screening for SMA by the end of 2022. Galicia has one of the most comprehensive newborn screening programmes in Spain. There are currently three ongoing pilots for SMA newborn screening in Spain: Valencia & Sevilla, Malaga, and Madrid. Read the original Spanish article here.

Read the new article published in August 2022, written in part by SMA NBS Alliance members from the University of Groningen and Novartis Gene Therapies, about the cost-effectiveness of newborn screening for SMA in the Netherlands.